TARRYTOWN, N.Y. and PARIS, Sept. 11, 2024. Regeneron Pharmaceuticals, Inc. and Sanofi today announced that a Dupixent (dupilumab) confirmatory Phase 3...

TARRYTOWN, N.Y. and PARIS, Sept. 11, 2024. Regeneron Pharmaceuticals, Inc. and Sanofi today announced that a Dupixent (dupilumab) confirmatory Phase 3...

BIIB's pivotal mid to late-stage study evaluating a higher dosing regimen for Spinraza to treat SMA in infants meets the primary and secondary goals.

BIIB's pivotal mid to late-stage study evaluating a higher dosing regimen for Spinraza to treat SMA in infants meets the primary and secondary goals.

The phase III THRIVE study evaluating Viridian's veligrotug for treating active thyroid eye disease meets all primary and secondary endpoints.

Athira's phase II/III LIFT-AD study on fosgonimeton for treating mild-to-moderate Alzheimer's disease fails to meet primary and secondary endpoints.

Athira's phase II/III LIFT-AD study on fosgonimeton for treating mild-to-moderate Alzheimer's disease fails to meet primary and secondary endpoints.

REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.

GILD reports the success of its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, in a second late-stage study for the prevention of HIV.

Data from two late-stage studies show that LLY's once-weekly insulin injections achieved results that are similar to daily insulin shots.